Effect of halofenate on serum lipids

Abstract

Forty‐eight people with hypertriglyceridemia associated with types III, IV, V, and nondefinitive lipoprotein patterns participated in a double‐blind 14 month study to determine the effects of halofenate on serum lipids. One month after starting dietary control, a 2 month control period began. After this, 25 patients were given placebo and 23 patients were given halofenate for 48 weeks. Five of the 35 patients with coronary heart disease developed a myocardial infarction and died within 14 months. Halofenate lowered mean serum triglyceride levels 49%j from the control period in comparison with placebo but did not significantly tower mean serum cholesterollevels. Halofenate also did not significantly affect myocardial infarction or mortality rate.